BIOLINERX     Print Page  Close Window

SEC filings
F-1
BIOLINERX LTD. filed this Form F-1 on 10/02/2012
Entire Document
 
F - 37

 
 
BioLineRx Ltd.
 
NOTES TO THE FINANCIAL STATEMENTS
 
NOTE 9 – EQUITY (cont.)

 
2)
Employee stock options

The following table contains additional information concerning options granted to employees and directors under the existing stock-option plans.
 
   
Year ended December 31,
 
   
2009
   
2010
   
2011
 
   
Number
of options
   
Weighted average exercise price
(in NIS)
   
Number
of options
   
Weighted average exercise price
(in NIS)
   
Number
of options
   
Weighted average exercise price
(in NIS)
 
Outstanding at beginning of year
    5,509,986       1.16       2,053,551       2.44       6,461,975       3.56  
Granted
    198,330       2.31       4,905,400       4.11       462,200       1.33  
Forfeited
    (658,137 )     2.61       (443,873 )     4.89       (1,336,974 )     3.75  
Exercised
    (2,996,628 )     0.04       (53,103 )     0.46       (29,481 )     0.04  
Outstanding at end of year
    2,053,551       2.44       6,461,975       3.56       5,557,720       1.87  
Exercisable at end of year
    689,946       2.92       1,120,270       1.69       1,362,970       1.96  

The total consideration received from the exercise of stock options during 2009, 2010 and 2011 was NIS 116,000, NIS 26,000 and NIS 1,000, respectively.

The weighted average prices of BioLineRx’s shares on the dates of exercise were NIS 2.42, NIS 3.53 and NIS 1.97 for 2009, 2010 and 2011, respectively.

See Note 9d(1) regarding the option re-pricing carried out in November 2011.